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Abstract
Background:  Hepatocellular carcinoma (HCC), a major cause of cancer death in China, is
preceded by chronic hepatitis and liver cirrhosis (LC). Although hepatitis B virus (HBV) has been
regarded as a clear etiology of human hepatocarcinogenesis, the mechanism is still needs to be
further clarified. In this study, we used a proteomic approach to identify the differential expression
protein profiles between HCC and the adjacent non-tumorous liver tissues.
Methods: Eighteen cases of HBV-related HCC including 12 cases of LC-developed HCC and 6
cases of chronic hepatitis B (CHB)-developed HCC were analyzed by two-dimensional
electrophoresis (2-DE) combined with matrix-assisted laser desorption/ionization time of flight
mass spectrometry (MALDI-TOF-MS), and the results were compared to those of paired adjacent
non-tumorous liver tissues.
Results: A total of 17 differentially expressed proteins with diverse biological functions were
identified. Among these, 10 proteins were up-regulated, whereas the other 7 proteins were down-
regulated in cancerous tissues. Two proteins, c-Jun N-terminal kinase 2 and ADP/ATP carrier
protein were found to be up-regulated only in CHB-developed HCC tissues. Insulin-like growth
factor binding protein 2 and Rho-GTPase-activating protein 4 were down-regulated in LC-
developed and CHB-developed HCC tissues, respectively. Although 11 out of these 17 proteins
have been already described by previous studies, or are already known to be involved in
hepatocarcinogenesis, this study revealed 6 new proteins differentially expressed in HBV-related
HCC.
Conclusion: These findings elucidate that there are common features between CHB-developed
HCC and LC-developed HCC. The identified proteins are valuable for studying the
hepatocarcinogenesis, and may be potential diagnostic markers or therapeutic targets for HBV-
related HCC.
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Introduction
Hepatitis B virus (HBV)-related hepatocellular carcinoma
(HCC) is one of the most common malignancy in the
world, especially in China [1,2]. HCC is usually preceded
by chronic hepatitis and liver cirrhosis (LC). The common
clinical evolution from chronic hepatitis, LC and ulti-
mately to HCC suggests that the carcinogenesis of HCC is
a complex process involving multiple events and steps.
Some molecular pathogenesis studies have been under-
taken successfully on the gene (DNA) and transcription
(mRNA) levels, however the carcinogenic mechanism of
HBV-related HCC still remains poorly understood.
Development of high throughput proteomics approach
provides a new tool to study the pathogenesis of HCC [3].
Proteomics has been used to characterize the molecular
events occurring in various disease processes. The two-
dimensional electrophoresis (2-DE) followed by mass
spectrometry (MS) analysis is the principal step of pro-
teomics to identify the comparative expression profiles at
the protein level that may be associated with specific dis-
eases. Such approaches are expected to establish the
molecular definition of the nontumor and tumor states
and contribute to the discovery of diagnostic markers and
therapeutic targets.
There are already some previous proteomic studies for
HCC, yet the proteomic analysis of HBV-related hepato-
carcinogenesis still needs to be further clarified. The aim
of the present study was to carry out a differential profil-
ing of proteins from HBV-related HCC samples and their
corresponding adjacent non-tumorous liver tissues
including chronic hepatitis and LC tissue using matrix-
assisted laser desorption/ionization time of flight mass
spectrometry (MALDI-TOF-MS). The results presented
here are expected to obtain some clues to further study the
carcinogenic mechanisms, or identify some possible
molecular markers for HBV-related HCC.
Materials and methods
Materials and chemicals
2-DE equipment, Imagescanner, ImageMaster 2D Elite
4.01 analysis software, semi-dry system (TE70 series Semi-
Dry Transfer Unit), protein assay kit and supply materials
(Immobiline DryStrips pH 3–10L, 24 cm, 13 cm, pharm-
alytes) were purchased from Amersham Biosciences.
Other chemicals were mainly obtained from Amersham
Biosciences. Trypsin was obtained from Sigma. All chem-
icals were of analytical reagent grade. Applied Biosystem
Voyager -DETM STR Biospectrometry™ workstation Sys-
tem 4307 MALDI-TOF-MS was purchased from Applied
Biosystems.
Liver tissue samples
Human liver tissue samples used in this study were
selected from 18 patients who had undergone partial
hepatectomy for HBV-related HCC at the Xiangya Hospi-
tal during the period 2003 2005 [see Table 1]. All HCC
patients were diagnosed based on clinical data, including
image evidence, histopathological examination [4], and
there was no evidence of co-infection with other hepato-
tropic viruses. Further possible causes of liver damage,
such as alcohol, drugs or autoimmune diseases were also
excluded. According to Edmonson pathologic grading,
Table 1: The main chracteristics of 18 HCC cases
Case Gender Age (years) HBV infection HCV Histopathologic diagnosis of adjacent non-tumorous tissues
HbsAg HbeAg anti-HBc DNA RNA
1 M 48 + + + + - liver cirrhosis
2 M 46 + + + + - liver cirrhosis
3 F 72 + + + + - liver cirrhosis
4 M 28 + + + + - liver cirrhosis
5 M 55 + + + + - chronic hepatitis
6 F 26 + + + - chronic hepatitis
7 M 58 + + + + - liver cirrhosis
8 M 25 + + + + - liver cirrhosis
9 M 41 + + + - liver cirrhosis
10 M 36 + + + + - chronic hepatitis
11 M 48 + + + + - liver cirrhosis
12 F 62 + + + + - liver cirrhosis
13 M 39 + + + - chronic hepatitis
14 M 44 + + + + - liver cirrhosis
15 M 50 + + + + - liver cirrhosis
16 M 38 + + + + - chronic hepatitis
17 F 41 + + + + - chronic hepatitis
18 M 65 + + + - liver cirrhosisJournal of Experimental & Clinical Cancer Research 2009, 28:122 http://www.jeccr.com/content/28/1/122
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the18 cases are all grade I. Compared to the tumorous
liver tissue, 18 nontumorous liver specimens (taken at a
distance of at least 2 cm from the tumor) including 12 cir-
rhotic tissue (LC) samples and 6 chronic hepatitis B
(CHB) tissue samples were also obtained from the same
individuals respectively [5]. Both LC tissues and CHB tis-
sues were diagnosed by pathological confirmation. The
study was approved by the hospital ethnic committee, and
all patients in the study were consentient before tissue
donation.
The preparation of tissue protein samples was described
previously by Li. et al.[6]. Briefly, representative fragments
of tumorous and non-tumorous liver tissue were immedi-
ately used to extract the total proteins, or were snap-frozen
in liquid nitrogen and stored at -80°C until used for liver
protein preparation. The specimens were then carefully
sampled, fixed in 10% formalin, embedded in paraffin
and routinely processed for diagnosis purposes. A total of
30~80 mg tissues were grinded into powder in liquid
nitrogen, dissolved in 400 μl lysis buffer consisting of 7
mol/L urea, 2 mol/L thiourea, 2% NP-40, 1% Triton X-
100, 100 mmol/L DTT, 5 mmol/L PMSF, 4% CHAPS, 0.5
mmol/L EDTA, 40 mmol/L Tris, 2% pharmalyte, 1 mg/ml
DNase I, and 0.25 mg/ml RNase A, then vortexed, incu-
bated at room temperature for 2 hr. The mixture was cen-
trifuged (15000 r/min, 30 min, 4°C). The supernatant
was the total protein solution. The concentration of the
total proteins was assayed with the protein assay kit
(Amersham Biosciences) by comparison of the absorb-
ance of the diluted mixtures to a standard curve of bovine
serum albumin in the range of 0–50 μg/L.
2-DE and image analysis
2-DE was performed to separate proteins as described in
our previous papers [6-8]. The first dimension isoelectric
focusing (IEF) electrophoresis was performed using IPG
gel strip (pH 3–10 NL, 24 cm) on IPGphor (Amersham
Biosciences). Briefly, 400 μg of protein samples was
diluted to 450 μL with a rehydration solution [7 mol/L
urea, 2 mol/L thiourea, 0.2% DTT and 0.5% (v/v) pH 3–
10 IPG buffer], and applied to IPG strips (pH 3–10L, 24
cm) by 14 h ehydration at 30 V. The proteins were focused
successively for 1 h at 500 V, 1 h at 1,000 V, and 8.5 h at
8,000 V to give a total of 68 kVh on an IPGphor. Focused
IPG strips were equilibrated for 15 min in a solution [6
mol/L urea, 2% SDS, 30% glycerol, 50 mmol/L Tris-HCl
(pH 8.8), and 1% DTT], and then for an additional 15
min in the same solution except that DTT was replaced by
2.5% iodoacetamide. After equilibration, SDS-PAGE was
done on Ettan DALT II system (Amersham Biosciences).
After SDS-PAGE, gels were stained with silver nitrate
according to the protocol of Plusone sliver staining kit
(Amersham Biosciences). Each experiment was performed
in triplicate.
2-DE maps were obtained by scanning the gels using the
Imagescanner. Analysis of the gels was accomplished
using the PDQuest analysis software including back-
ground subtraction, spots detection, volume normaliza-
tion and the establishment of a reference gel. Intensity of
each protein was quantified by calculation of spot volume
after normalization of the image using the total spot vol-
ume normalization method multiplied by the total area of
all the spots. The calculation of the theoretical molecular
weight and pI values of the identified protein spots is
based on algorithms included in the ImageMaster 2D Elite
4.01 analysis software package. Statistical analysis was car-
ried out with SPSS for Windows 10.0 and Excel.
MALDI-TOF-MS
Differential protein spots were excised from preparative
gels using biopsy punches and transferred to a 1.5 ml sili-
conized Eppendorf tube. Proteins in-gel was digested as
previously described [6]. The gel-spots were destained in
the destaining solution consisted of 100 mmol/L Na2S2O3
and 30 mmol/L K3Fe(CN)6 (1:1). The proteins-contained
gel-spots were reduced in the reduction buffer consisted of
100 mmol/L NH4HCO3, 10 mmol/L DTT for 1 h at 57°C,
and alkylated in the alkylation buffer consisted of 100
mmol/L NH4HCO3and 55 mmol/L iodocetamide in the
dark for 30 min at room temperature. The gel pieces were
dried in a vacuum centrifuge. The dried gel-pieces were
incubated in the digestion solution consisted of 40 mmol/
L NH4HCO3, 9%ACN and 20 μg/mL trypsin(Sigma, St.
Louis, USA) for 16 h at 37°C. The tryptic peptide mixture
was extracted and purified with Millipore ZIPTIP™C18
column. The purified tryptic peptide mixture was mixed
with α-cyano-4-hydroxycinnamic acid (CCA) matrix solu-
tion, and vortexed lightly. A volume (1 μl) of the mixture
containing CCA matrix was loaded on a stainless steel
plate, and dried in the air. The samples were analyzed
with Applied Biosystems Voyager System 4307 MALDI-
TOF Mass Spectrometer (ABI). The parameters were set up
as following: positive ion-reflector mode, accelerating
voltage 20 kV, grid voltage 64.5%, mirror voltage ratio
1.12, N2 laser wavelength 337 nm, pulse width 3 ns, the
number of laser shots 50, acquisition mass range 1000–
3000 Da, and delay 100 nsec, and vacuum degree 4×10-
7Torr. A trypsin-fragment peak was served as internal
standard for mass calibration. A list of the corrected mass
peaks was the peptide mass fingerprinting (PMF).
Database analysis
Proteins were identified with peptide mass fingerprinting
data by searching software PeptIdent http://
www.expasy.org/ and Mascot http://www.matrix sci-
ence.com. Mascot Distiller was used to detect peaks by
attempting to fit an ideal isotopic distribution to the
experimental data. The searching parameters were set up
as following[6,7]: the mass tolerance was ± 0.5 Dalton;Journal of Experimental & Clinical Cancer Research 2009, 28:122 http://www.jeccr.com/content/28/1/122
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the number of missed cleavage sites was allowed up to 1;
the cysteine residue was modified as carbamidomethyl-
cys; variable modifications was oxidation (M); the mini-
mum number of matched-peptides was 5; species was
selected as homo sapiens(Human); the peptide ion was
[M+H]+; Mass values was monoisotopic; the searching
range was within the experimental pI value ± 0.5 pH unit
and experimental Mr ± 20%.
Results
2-DE maps for human liver tissue proteome
In order to validate the reproducibility, 2-DEs for 18 cases
of HBV-related HCC including 12 cases of LC-developed
HCC and 6 cases of CHB-developed HCC were repeated
for three times. The image analysis showed that these 2-
DE maps were reproducible. Using this technique, Over
1,000 protein spots were clearly separated on the gels,
ranging from 1100–1400 massed between pH 3–10 in
three different tissues. A total of 100 well-resolved and
matched spots among three tumor-gels were chosen ran-
domly to calculate the deviation of the spot position. The
spot positional deviation was 2.47. ± 0.25 mm in the IEF
direction, and 2.86 ± 0.25 mm in SDS-PAGE direction.
For 12 cases of HCC developed from LC, a total of 1281 ±
51 spots were detected in tumorous tissues with an aver-
age matching rate of 94.38%, while a total of 1188 ± 41
spots were detected in LC tissues, with an average match-
ing rate of 94.95%. For 6 cases of HCC developed from
CHB, a total of 1245 ± 37 spots were detected in tumor tis-
sues with an average matching rate of 94.69%, while a
total of 1235 ± 31 spots were detected in hepatitis tissues
with an average matching rate of 95.55%. The well-
resolved and reproducible 2-DE patterns of HBV-related
HCC tissues and non-tumorous liver tissues adjacent to
tumors were attained, which are displayed in Figure 1 and
Figure 2.
In this study, the 2-DE protein patterns of 12 pairs of
tumor/cirrhosis samples and 6 pairs of tumor/hepatitis
samples were quantified and mutually matched. In order
to preselect protein variations, the protein patterns of
tumor and nontumor tissues were set into two classes, and
quantities of all detected spots in both classes were com-
pared by the Student's t-test in ImageMaster 2-DE gel anal-
ysis software [6,8]. The 2-DE profiles were very similar
among 18 tumor tissues samples. To construct a 2-DE
map, it is important to have a representative sample.
Hence, an average electrophoretic map of human HBV-
related HCC tissues was constructed by the comparison of
the 2-DE maps from 18 tumor tissues with the ImageMas-
ter 2-DE gel analysis software. The average electrophoresis
map included 2076 protein-spots. Similarly, two average
electrophoresis maps of 12 cirrhotic tissues and 6 hepati-
tis tissues were also established with 1987 protein-spots
and 1899 protein-spots, respectively. These average elec-
trophoresis maps were used to perform the differential
expression analysis. The Differential protein spots were
defined as spots in 2-DE gels whose expression up-regu-
lated significantly (at least three-fold discrepancy) in
more than 50% certain tissue compared with control tis-
sue. We compared the 2-DE protein patterns of the aver-
age gels of tumorous and cirrhotic tissue, 35 differential
protein-spots were detected, among which 19 proteins
were up-regulated in tumorous tissues, and 16 were up-
regulated in cirrhotic tissues significantly. As shown in
Figure 1, the spots numbers in part A stood for the pro-
teins which were only expressed or over-expressed in
tumorous tissues, and the spots numbers in part B stood
for the proteins which were only expressed in cirrhotic tis-
sues or down-regulated in tumorous tissues. We also com-
pared the differential protein expression of paired
tumorous and chronic hepatitis B liver tissues from 6
patients with HCC. We found that there were 38 differen-
tial spots between cancerous tissues and chronic hepatitis
tissues, of which 21 differential protein spots were up-reg-
ulated in cancerous tissues, while 17 differential protein
spots were up-regulated in chronic hepatitis tissues. As
shown in Figure 2, the spots numbers in part A stood for
the proteins which were only expressed or over-expressed
in tumorous tissues, and the spots numbers in part B
stood for the proteins which were only expressed in
chronic hepatitis tissues or down-regulated in tumorous
tissues.
Identification of differentially expressed proteins in HCC 
developed from LC
The differential protein-spots were excised from the silver
stained gels, and digested in-gel with trypsin. The peptide
mass fingerprinting (PMF) maps were obtained by
MALDI-TOF-MS, and calibrated with Trypsin auto-
degraded peak (m/z = 1993.9772 Da). A selected PMF of
protein spot 6 was display in Figure 3. The PMF data were
used to search the SWISS-PROT, TrEMBL and NCBI data-
bases with PeptIdent or Mascot software. The resulting
protein was determined by comprehensively considering
the corresponding experimental pI, Mr, the number of
matched-peptides, and the sequence coverage. Among the
35 protein spots, PMF maps of 23 proteins were obtained
by MALDI-TOF-MS, and 14 differential proteins were
identified. Of the 14 identified proteins, the expressional
levels of 8 proteins named Cytoplasmic dynein heavy
chain, Nucleolar phosphoprotein B23, Gankyrin,
Cytoskeletal 8, Alpha-1-fetoprotein, Lamin B1, Insulin-
stimulated protein kinase 1 and Cell division cycle pro-
tein 27 homolog (CDC27Hs) were up-regulated in can-
cerous tissues [see Additional file 1], whereas the
expressional levels of 6 proteins named Cyclin-dependent
kinase inhibitor p12, Cyclin-dependent kinase inhibitor
1, Antioxidant protein 2, Protein disulfide isomerase A2,
C-1-tetrahydrofolate synthase and Insulin-like growth fac-Journal of Experimental & Clinical Cancer Research 2009, 28:122 http://www.jeccr.com/content/28/1/122
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Representative silver-stained 2-DE proteins maps obtained from (A) HCC tumorous tissue and (B) adjacent paired liver cirrho- sis tissue Figure 1
Representative silver-stained 2-DE proteins maps obtained from (A) HCC tumorous tissue and (B) adjacent 
paired liver cirrhosis tissue. The circled protein spots with Arabic numbers in (A) were up-regulated in tumorous tissues. 
The circled protein spots with English letters in (B) were up-regulated in cirrhotic tissues.Journal of Experimental & Clinical Cancer Research 2009, 28:122 http://www.jeccr.com/content/28/1/122
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Representative silver-stained 2-DE proteins maps obtained from (A) HCC tumorous tissue and (B) adjacent paired chronic  hepatitis tissue Figure 2
Representative silver-stained 2-DE proteins maps obtained from (A) HCC tumorous tissue and (B) adjacent 
paired chronic hepatitis tissue. The circled protein spots with Arabic numbers in (A) were up-regulated in tumorous tis-
sues. The circled protein spots with English letters in (B) were up-regulated in chronic hepatitis tissues.Journal of Experimental & Clinical Cancer Research 2009, 28:122 http://www.jeccr.com/content/28/1/122
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tor binding protein 2 were up-regulated in cirrhotic tissues
[see Additional file 1].
Identification of differentially expressed proteins in HCC 
developed from CHB
Thirty eight differential spots between cancerous tissues
and chronic hepatitis tissues had been observed. Using
MALDI-TOF-MS, 24 PMF were successfully obtained, and
16 proteins were identified. Among the 16 identified pro-
teins, 10 proteins were found to be up-regulated in HCC
developed from CHB. The up-regulated 10 proteins
included 8 above described proteins over-expressed in
HCC developed from LC and other two proteins named c-
Jun N-terminal kinase 2 and ADP/ATP carrier protein [see
MALDI-TOF-MS analysis of differential protein spot 6 Figure 3
MALDI-TOF-MS analysis of differential protein spot 6. (A) The MALDI-TOF-MS mass spectrum of spot 6, identified as 
the Gankyrin according to the matched peaks is shown. (B) Protein sequence of Gankyrin is shown, and matched peptides are 
indicated in bold font and underlined.Journal of Experimental & Clinical Cancer Research 2009, 28:122 http://www.jeccr.com/content/28/1/122
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Additional file 1]. Six proteins out of 16 identified pro-
teins including 5 above-mentioned proteins which were
up-regulated in cirrhotic tissues (Cyclin-dependent kinase
inhibitor p12, Cyclin-dependent kinase inhibitor 1, Anti-
oxidant protein 2, Protein disulfide isomerase A2, C1-tet-
rahydrofolate synthase) and Rho-GTPase-activating
protein 4 were up-regulated in chronic hepatitis tissues
[see Additional file 1].
Discussion
HCC is one of the most fatal cancers worldwide, and it is
responsible for approximately one million deaths each
year. Though the HBV infection is regarded as the most
clearly established risk factors, the mechanism is complex
and the distinct molecular pathway or molecules involved
this phenomenon still remains poorly understood. The
possible carcinogenic mechanism of HBV-related HCC is
related to the long term-inflammatory changes caused by
HBV infection. Chronic hepatitis and cirrhosis are two
phases of hepatic necrotizing inflammation caused by
HBV infection. Each year, approximate 2%~3% patients
with LC will develop HCC, and 0.2% patients with CHB
will develop HCC [9,10]. Few studies have been reported
concerning the difference between LC-developed HCC
and CHB-developed HCC.
MALDI-TOF-MS is a new technique identifying proteins.
Since it can rapidly provide a protein expression profile
from a variety of biological and clinical samples, many
tumorous tissues proteomic studies have been carried out
by using this system [11-13]. In this study, the compara-
tive proteomic study was performed between the HCC tis-
sues and the adjacent no-tumorous tissues including CHB
and LC tissues. Seventeen differential protein-spots were
identified by MALDI-TOF-MS-based PMF analysis. Eight
out of 17 proteins were found to be up-regulated in
tumorous tissues of HCC developed from CHB as well as
developed from LC. These included Cytoplasmic dynein
heavy chain, Nucleolar phosphoprotein B23, Gankyrin,
Cytoskeletal 8, Alpha-1-fetoprotein, Lamin B1, Insulin-
stimulated protein kinase 1 and Protein CDC27HS.
Meanwhile, five out of 17 proteins, named Cyclin-
dependent kinase inhibitor p12, Cyclin-dependent kinase
inhibitor 1, Antioxidant protein 2, Protein disulfide iso-
merase A2, C1-tetrahydrofolate synthase were down-regu-
lated both in LC-developed HCC and CHB-developed
HCC. However, two identified proteins, c-Jun N-terminal
kinase 2 and ADP/ATP carrier protein were found to be
up-regulated only in CHB-developed HCC tumorous tis-
sues. The expressions of insulin-like growth factor binding
protein 2 and Rho-GTPase-activating protein 4 were up-
regulated in LC liver tissues and CHB liver tissues, respec-
tively. Classification of all proteins [see Additional file 1]
showed that HCC is such a complicated disease involving
multiple-aspects and genes in the differentially expressed
proteome at the level of whole-cell extract. Although a few
special proteins differentially expressed in CHB-devel-
oped HCC or LC-developed HCC, most of identified pro-
teins expressed in both CHB-developed HCC and LC-
developed HCC, which indicates that there are common
features between CHB-developed HCC and LC-developed
HCC.
Among the 17 proteins identified in this study, 11 pro-
teins have been already described by previous studies, or
are already known to be involved in hepatocarcinogene-
sis. These proteins are involved in cell growth, prolifera-
tion, differentiation, metabolism, cell cycle regulation,
cytoskeleton and signal transduction. Importantly, 6
novel proteins including 3 up-regulated proteins
(CDC27Hs, ADP/ATP carrier protein, Insulin-stimulated
protein kinase 1) and 3 down-regulated proteins (Rho-
GTPase-activating protein 4, Antioxidant protein 2, C1-
tetrahydrofolate synthase), were identified in our study.
Although these proteins were obtained on a limited
number of patients, it should be pointed out that our
analysis correctly identified the vast majority of the pro-
teins previously known to be regulated in HCC. It is thus
reasonable to assume that the newly identified proteins
may be involved in the development of hepatocarcino-
genesis or are potential markers of HCC. As a cell cycle
regulator, CDC27Hs colocalizes to the centrosome at all
stages of the mammalian cell cycle, and to the mitotic
spindle. Injection of affinity-purified anti-CDC27Hs anti-
bodies into logarithmically growing HeLa cells caused a
highly reproducible cell cycle arrest in metaphase with
apparently normal spindle structure [14]. Some studies
indicated that CDC27Hs may be involved in the cancer
cell growth [15,16]. The role of CDC27Hs in hepatocar-
cinogenesis needs further study. ADP/ATP carrier protein
(AAC) was found to be up-regulated in a larger series of
HCC tissues in this study, but down-regulated in notu-
morous tissues especially in chronic hepatitis B tissues.
AAC is an integral protein present in the inner mitochon-
drial membrane, which performs the exchange of cyto-
plasmic and intramitochondrial ADP and ATP. Schulze et
al considered the dysfunction of ACC can be induced by
some viral infection such as coxsackie B3 virus and leads
to an imbalance in myocardial energy metabolism, which
is responsible for the impairment of cardiac function
[17,18]. Recently, the over expression of AAC has already
been observed in breast cancer cell [19], and AAC was
regarded as a potential biomarker for therapy and progno-
sis in breast cancer.
The 3 novel down-regulated proteins in this study are
mainly involved in metabolism, oxidative stress and pro-
liferation. Rho-GTPase-activating protein 4 (ARHGAP4) is
a member of the Rho GTPase activating protein
(RhoGAP) family. The RhoGAP family proteins play anJournal of Experimental & Clinical Cancer Research 2009, 28:122 http://www.jeccr.com/content/28/1/122
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important role in regulating cell migration, cell morphol-
ogy and cytoskeletal or ganization [20]. The RhoGAP tran-
scripts were found to be truncated or lowly expressed in
some breast carcinoma cell lines, indicating that loss of
RhoGAP or its altered activity may suppresse the growth
of breast tumor cells [21]. Deleted in liver cancer-1 gene
(DLC-1) which is isolated from human hepatocellular
carcinoma and encodes a Rho GTPase-activating protein,
is frequently inactivated or down-regulated in liver and
prostate carcinoma cells [22]. As a tumor suppressor gene,
DLC1 significantly inhibits cell proliferation, reduced the
motility and invasiveness of hepatocellular carcinoma
cells [23]. Our results in this study showed a low expres-
sion of ARHGAP4 at the protein level in 83% of 6 human
HCC tested [see Additional file 1]. However, no data have
been given to demonstrate the role of ARHGAP4 in hepa-
tocarcinogenesis till now, and the relationship between
ARHGAP4 and DLC1 need to be further evaluated. Anti-
oxidant protein 2(AOP2), a unique member of the thiol-
specific antioxidant family of proteins, has been shown to
remove H2O2 and protect proteins and DNA from oxida-
tive stress [24,25]. Oxidative damage usually leads to
decrease ATP level and consequently play an important
role in carcinogenesis and metastasis of HCC [26,27].
Increased expression of the stress proteins such as HSP,
heat shock cognate (HSC), glucose-regulated protein
(GRP) and glycolytic enzymes was found in HCC using 2-
DE-based proteomics [28]. Ezzikouri et al further defined
that hepatitis B and C viruses may induce chronic inflam-
mation and oxidative stress, which could predispose a cell
to mutagenesis and proliferation [29]. Decreased expres-
sion of AOP2 has been previously reported in human
prostate cancer [30] and colon cancer cells [31]. In this
study, AOP2 was firstly found to be down-regulated in
HCC tissues, indicating that HCC cells are in a state of ele-
vated stress and stimulated metabolism. C(1)-tetrahydro-
folate (THF) synthase, the eukaryotic trifunctional
enzyme, interconvert folic acid derivatives between vari-
ous oxidation states and is critical for normal cellular
function, growth, and differentiation [32]. Howard et al
found that the expression patterns of C(1)-THF synthase
was involved in liver regeneration [33]. The function and
acting mechanisms of this protein await further study.
In conclusion, using 2-DE combined with MS and a strin-
gent statistical analysis, we have been able to identify the
differentially proteomic analysis of human HBV-related
HCC developed from CHB or LC. Several identified pro-
teins may be potential tumor markers or promising new
candidate actors for liver carcinogenesis. Functional stud-
ies on selected targets are underway to confirm this
hypothesis.
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